title: Advances in the understanding, management, and prevention of dengue.
abstract: Dengue causes more human morbidity globally than any other vector-borne viral disease. Recent research has led to improved epidemiological methods that predict disease burden and factors involved in transmission, a better understanding of immune responses in infection, and enhanced animal models. In addition, a number of control measures, including preventative vaccines, are in clinical trials. However, significant gaps remain, including the need for better surveillance in large parts of the world, methods to predict which individuals will develop severe disease, and immunologic correlates of protection against dengue illness. During the next decade, dengue will likely expand its geographic reach and become an increasing burden on health resources in affected areas. Licensed vaccines and antiviral agents are needed in order to effectively control dengue and limit disease.
authors.affiliation: Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Department of Virology, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.
authors.forename: Laura L
authors.initials: LL
authors.lastname: Hermann
authors.affiliation: Merck and Company, 351 North Sumneytown Pike, North Wales, PA 19454, United States.
authors.forename: Swati B
authors.initials: SB
authors.lastname: Gupta
authors.affiliation: Merck and Company, 351 North Sumneytown Pike, North Wales, PA 19454, United States.
authors.forename: Susan B
authors.initials: SB
authors.lastname: Manoff
authors.affiliation: Queen Sirikit National Institute of Child Health, Bangkok, Thailand.
authors.forename: Siripen
authors.initials: S
authors.lastname: Kalayanarooj
authors.affiliation: Department of Virology, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.
authors.forename: Robert V
authors.initials: RV
authors.lastname: Gibbons
authors.affiliation: Merck and Company, 351 North Sumneytown Pike, North Wales, PA 19454, United States. Electronic address: beth-ann.coller@merck.com.
authors.forename: Beth-Ann G
authors.initials: BA
authors.lastname: Coller
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use; D003715:Dengue / Q000453:epidemiology* / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D053059:Dengue Vaccines / Q000276:immunology; D019468:Disease Management; D006801:Humans
chemical_list: D000998:Antiviral Agents; D053059:Dengue Vaccines
keywords: Dengue; Diagnosis; Epidemiology; Treatment; Vaccine